Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting (TRIMAXIMIZE)

Chiesi

Status: Active, not recruiting

Conditions: Asthma

Treatments: Drug: BDP/FF/G

Study type: Observational

Funder types: Industry

Identifiers

NCT06100042

NIS 005 Pn (Other Identifier)

CHIT-2301

Details and patient eligibility

About

TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G (beclomethasone/formoterol/glycopyrronium).

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥ 18 years of age;
• Patients with confirmed leading diagnosis of asthma with or without concomitant COPD;
• Physician decision to start fixed triple therapy with ICS/LABA/LAMA (BDP/FF/G) MS or HS according to its current authorised indication and current reimbursement conditions within the Italian National Health System. The treatment decision must be made independently from participation in this study and may have started within the previous 4 weeks (maximum);
• Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.

Exclusion criteria

• Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.

Trial design

200 participants in 1 patient group

Asthma patients

Description:

Adult patients with a diagnosis of moderate to severe asthma treated with BDP/FF/G medium strength or high strength as per clinical practice.

Treatment:

Drug: BDP/FF/G